1342.1 - Oncotype DX breast cancer assay to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit (Resubmission)

Page last updated: 11 July 2016

Application Detail

Status

Closed

Description of Medical Service

Oncotype DX is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.

Description of Medical Condition

Outside Australia, Oncotype DX is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.

Reason for Application

New MBS item

Medical Service Type

Investigative

Previous Application Number

1342

Associated Documentation

Application Form

-

PICO Confirmation

Please see Application 1342

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 58 KB)
Public Summary Document (Word 143 KB)

Meetings for this Application

PASC

-

ESC

13 -14 February 2014

MSAC

3 - 4 April 2014